Latest News and Press Releases

The Annual General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 11 April 2018 at 10:00 CET. Please find the notice including agenda for the General Meeting and...

Reference is made to the extraordinary general meeting of Targovax ASA (the "Company") on 30 November 2017, where Patrick Vink was elected as chairman of the Company's board of directors and the...

Oslo, Norway, 27 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company will present at...

Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017...

Oslo, Norway, 7 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces completion of the safety...

Oslo, Norway, 6 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter 2018...

With reference to the Stock exchange notification issued 1 February 2018 regarding options to employees: The exercise price of the granted options is NOK 17.17. The exercise price is equal to the...

On the basis of the approval by the Annual General Meeting on 5 April 2017 to authorize the Board of Targovax ASA to issue new shares to employees under the Company long-term incentive program, the...

Oslo, Norway, 8 January 2018: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that...

Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the...